Study of Acquired Immunity in Patients With Lung Cancer and COVID-19 Infection
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 1,980
- 试验地点
- 68
- 主要终点
- Description of the characteristics of patients
研究概览
简要总结
Observational, retrospective data collection and prospective IgG analysis, and multicenter study.
The main objective of the study is th description of the characteristics and evolution of patients with lung cancer who have acquired COVID-19 infection.
For the identification of patients who contract COVID-19 infection, the IgG+ blood test by ELISA method will be used.
详细描述
Non-post-authorization study, retrospective of data collection and prospective of IgG analysis, observational and multicenter.
The study will be extended to all the sites of the Spanish Lung Cancer Group, more than 170 centers and 500 professionals, and it is expected that around 1,500 IgG tests will be carried out.
The study has three phases:
The scope of phase I is the identification of acquired immunity (IgG) in patients with lung cancer, whether or not they have presented symptoms of having suffered from COVID19. In addition, the description of the characteristics and evolution of patients with lung cancer who have contracted COVID-19 infection will be carried out.
For the identification of patients who contract COVID-19 infection, the IgG+ test in blood will be used by ELISA method.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients diagnosed with lung cancer at any stage of the disease
- •Patients who have signed the informed consent for this study
排除标准
- •1. Patients who have not signed or do not wish to sign the informed consent for this study
研究组 & 干预措施
lung cancer+COVID-19
Lung cancer patients infected by COVID-19
干预措施: IgG test (Diagnostic Test)
结局指标
主要结局
Description of the characteristics of patients
时间窗: From the diagnosis of the COVID until the determination of the blood IgGs, up to 10 weeks
Description of the characteristics and evolution of patients with lung cancer who have contracted COVID-19 infection.
次要结局
- Detection of antibodies (IgG) at 6 months after SARS-COV2 vaccines(From the date of complete SARS-COV2 vaccination administration until 6 month)